Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Khan Hameed

Vascular Surgery West Covina, CA Medical Doctor

NPI 1558329623 CMS profile 721157

1135 S Sunset Ave Ste 305, West Covina, CA 91790

Open in the dashboard

General payments

$3,826

102 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Khan Hameed of West Covina, CA is reported in the CMS Open Payments database as having received $3,826 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $340 13
2024 General $879 19
2023 General $749 16
2022 General $881 16
2021 General $466 14
2020 General $351 15
2019 General $160 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Khan Hameed
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Khan Hameed were reported at $340. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Khan Hameed Vascular Surgery median Middle half National median
2019 $160 $796 $226–$2,363 $163
2020 $351 $348 $118–$1,110 $114
2021 $466 $471 $158–$1,421 $132
2022 $881 $725 $222–$2,183 $149
2023 $749 $836 $257–$2,440 $160
2024 $879 $909 $252–$2,619 $164
2025 $340 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inari Medical, Inc. $1,562 25 payments
  2. Medtronic, Inc. $429 13 payments
  3. Silk Road Medical, Inc. $322 16 payments
  4. TELA Bio, Inc. $275 6 payments
  5. W. L. Gore & Associates, Inc. $245 10 payments
  6. CVRx, Inc. $201 1 payment
  7. Medtronic Vascular, Inc. $180 9 payments
  8. Abiomed $123 1 payment
  9. Lilly USA, LLC $95 3 payments
  10. Abbott Laboratories $95 4 payments
  11. Other $298 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,780 101 payments
  2. Travel and Lodging $46 1 payment
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $1,608 26 payments
  2. CT THROMBECTOMY SYSTEM KIT $1,517 24 payments
  3. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $275 6 payments
  4. Barostim Neo System $201 1 payment
  5. ENROUTE Transcarotid Stent $199 10 payments
  6. ENROUTE Transcarotid Neuroprotection System $199 10 payments
  7. Valiant Captivia $166 8 payments
  8. CONCERTOTM $135 2 payments
  9. ENROUTE 0.014 Guidewire $123 6 payments
  10. ENROUTE Transcarotid Stent System $123 6 payments
  11. Other $1,745 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

177

Median for Vascular Surgery: 122

Drug cost

$22,049

Median for Vascular Surgery: $14,135

Branded share of claims

75.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 30 $21,031
Clopidogrel Clopidogrel Bisulfate Brand 49 $413
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 54 $374
Atorvastatin Calcium Generic 27 $121
Cilostazol Generic 17 $108

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$109,334

Medicare's payments for the services billed

Medicare patients

287

Average age 73

Services billed

722

131 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 74%
Chronic kidney disease 67%
Ischemic heart disease 54%
Heart failure 51%
Arthritis 50%
Atrial fibrillation 30%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record